CoreRx partners with leon-nanodrugs to offer nano-based MicroJet Reactor (MJR®) drug formulations
CLEARWATER, Fla. and MUNICH, March 22, 2016 /PRNewswire/ -- CoreRx Pharma and leon-nanodrugs announced a partnership today.
CoreRx and leon-nanodrugs are pleased to announce the cooperation for the establishment of a dedicated laboratory at the CoreRx Myerlake facility that will house leon-nanodrugs' proprietary nanotechnology platform – MicroJet Reactor (MJR). The lab will focus on technical feasibility work through final formulation for oral, semi-solid, and liquid preparations utilizing the novel MJR nanotechnology.
It is estimated that over 60% of pharmaceutical API's are poorly soluble in water. leon's MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous process approach of the MJR technology is highly cost effective and easily scalable.
leon-nanodrugs focuses on developing innovative drug formulations enabled by its proprietary nanotechnology platform – MicroJet Reactor (MJR). leon works with its Pharma customers through contract development agreements, as well as co-development partnerships. leon has also initiated work on its own internal development projects, concentrating on nanotechnology-based reformulations that offer enhanced clinical and safety benefits.
Todd Daviau, CEO of CoreRx states: "We are excited to join with leon-nanodrugs as we continue to build upon our service offerings and the capabilities which add value to our client's portfolios. By integrating our service offerings with the MJR capabilities, we will be able to do more in fewer steps – there are no scale-up issues with the MJR. For our clients, this will mean faster time to market. This service offering supports our mission to provide CoreRx's clients with unprecedented levels of innovation and industry-leading expertise to best advance their development and commercial pursuits. We believe this integration with leon will allow us to deliver greater speed to commercialization through exceptional science and extensive capabilities."
Dr. Theron E. Odlaug, CEO of leon-nanodrugs GmbH and the US subsidiary explains: "The vision of leon-nanodrugs is to be recognized as a global leader in nanotechnology formulated pharmaceuticals through contract services and co-development partnerships. Through the unique attributes of our MicroJet Reactor Technology, our goal is to generate added value to both established molecules and novel NCEs. The partnership with CoreRx represents a key step for leon as we can offer our Pharma partners a second state of the art facility for developing enhanced nanotechnology-enabled formulations for new and existing compounds."
About CoreRx:
CoreRx® a CDMO with a focus on early phase drug product development, offering state of the art facilities to support your supply chain needs throughout the entire clinical trial process. Our integrated offerings provide comprehensive services for the development, manufacturing and testing of solid, liquid and semi-solid dosage forms.
The art of drug product development is the core of what we do. We differentiate ourselves by mixing highly experienced scientists with a wide range of technologies to deliver optimal solutions to meet our clients' needs. From simple formulations to complex, delayed or targeted release dosage forms, CoreRx's solutions maximize client investments, shorten development time and reduce overall costs.
CONTACT:
Michelle Hall
(727) 259-6950
208-6116 – Cell
[email protected]
About leon:
leon-nanodrugs GmbH (based in Munich) is a nanotechnology-based drug development company focused on reformulations and reinventions of drugs on a contract or co-development basis. Based on its "network of expertise", leon-nanodrugs can provide a 360-degree service range – from concept to product approval. The core business is the reformulations to develop novel oral and parenteral formulations and innovative drug combinations, which have not been possible in the past due to low bioavailability caused by low solubility of APIs. The 2014 CPHI Pharma Awards for Best Innovation in Formulation was won by MJR PharmJet GmbH, one of leon's reformulation service partners (along with CoreRx in the USA), for its patented nanotechnology.
CONTACT:
Rick White
(847) 922-3781 leon-
nanodrugs Inc.
[email protected]
Logo - http://photos.prnewswire.com/prnh/20160321/346338LOGO
Logo - http://photos.prnewswire.com/prnh/20160321/346337LOGO
SOURCE CoreRx
Share this article